MDM2 oncogene as a target for cancer therapy: An antisense a…

Established

82
Citations
0
Refs
1999
Year
Search Works
Work Details
  • DOI 10.3892/ijo.15.4.653
  • PMID https://pubmed.ncbi.nlm.nih.gov/10493945
  • OpenAlex ID W2017492419
  • Type Article
  • Language EN
  • Published 01 Oct 1999
  • Volume 15 (4)
  • Pages 653–60
  • Source International Journal of Oncology
  • Publisher Spandidos Publishing
  • FWCI 2.84
  • Countries 1
  • Institutions 2
  • Added 24 Jun 2016
  • Updated 27 Oct 2026
External Links
OpenAlex Record DOI Resolver PubMed
MENU
0

MDM2 oncogene as a target for cancer therapy: An antisense approach.

Article 1999 EN

The MDM2 oncogene is amplified or overexpressed in human cancers. It has also been suggested that MDM2 levels are associated with poor prognosis of several human cancers. The MDM2 oncoprotein binds to the p53 tumor suppressor protein and serves as a negative regulator of p53. The p53 tumor suppressor also has an important role in cancer therapy, with p53-mediated apoptosis being a major mechanism…

82

Citations

0

References

9

Authors

2.84

FWCI

Citations by Year
Last 7 years
Topics
Keywords
UN Sustainable Development Goals
1 SDGs
Authors & Affiliations
9 authors
#AuthorInstitutionsORCID
1 Hui Wang University of Alabama at Birmi… (US) UAB Medicine (US) —
2 Xiaorong Zeng University of Alabama at Birmi… (US) UAB Medicine (US)
3 Patsy G. Oliver University of Alabama at Birmi… (US) UAB Medicine (US) —
4 Long P. Le University of Alabama at Birmi… (US) UAB Medicine (US)
5 J. Chen University of Alabama at Birmi… (US) UAB Medicine (US) —
6 Lei Chen University of Alabama at Birmi… (US) UAB Medicine (US)
7 Wei Zhou University of Alabama at Birmi… (US) UAB Medicine (US)
8 Sudhir Agrawal University of Alabama at Birmi… (US) UAB Medicine (US)
9 R Zhang University of Alabama at Birmi… (US) UAB Medicine (US)
Related Works
10

Data: OpenAlex